Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | EGFR | P00533 | 2/20 | 0.51 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.50 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 2/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | MIF | P14174 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22822783 | 1.00 | MAPT (0.66) | MAPTKDM4EALDH1A1LMNAMAPK1 | |
| SCHEMBL22462346 | 1.00 | MAPT (0.66) | MAPTKDM4EALDH1A1LMNAMAPK1 | |
| SCHEMBL22550922 | 0.85 | CYP1A2 (0.60) | MAPTALDH1A1LMNAMAPK1KMT2A | |
| SCHEMBL22550815 | 0.84 | KMT2A (0.54) | MAPTKDM4EALDH1A1LMNAMAPK1 | |
| SCHEMBL22529620 | 0.84 | KMT2A (0.54) | MAPTKDM4EALDH1A1LMNAMAPK1 | |
| SCHEMBL22529619 | 0.84 | KMT2A (0.54) | MAPTKDM4EALDH1A1LMNAMAPK1 | |
| SCHEMBL22462354 | 0.82 | MAPT (0.63) | MAPTKDM4EALDH1A1LMNAMAPK1 | |
| SCHEMBL22822875 | 0.82 | MAPT (0.63) | MAPTKDM4EALDH1A1LMNAMAPK1 | |
| SCHEMBL22462353 | 0.82 | MAPT (0.63) | MAPTKDM4EALDH1A1LMNAMAPK1 | |
| SCHEMBL22550769 | 0.80 | CYP1A2 (0.66) | MAPTKDM4EALDH1A1LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11964943-B2 | 3,5-diarylidenyl-n-substituted-piperid-4-one-derived inhibitors of Stat3 pathway activity and uses thereof | KIAKOS KONSTANTINOS (AT) | 2024-04-23 | — | — | US | disclosed |
| US-20200399220-A1 | 3,5-DIARYLIDENYL-N-SUBSTITUTED-PIPERID-4-ONE-DERIVED INHIBITORS OF STAT3 PATHWAY ACTIVITY AND USES THEREOF | KIAKOS KONSTANTINOS (AT) | 2020-12-24 | — | — | US | disclosed |
| WO-2019097080-A9 | 3,5-DIARYLIDENYL-N-SUBSTITUTED-PIPERID-4-ONE-DERIVED INHIBITORS OF STAT3 PATHWAY ACITIVTY AND USES THEROF | KIAKOS KONSTANTINOS (AT) | 2020-10-15 | — | — | WO | disclosed |
| EP-3713916-A1 | 3,5-DIARYLIDENYL-N-SUBSTITUTED-PIPERID-4-ONE-DERIVED INHIBITORS OF STAT3 PATHWAY ACITIVTY AND USES THEROF | Kiakos, Konstantinos (AT) | 2020-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11964943-B2 | 3,5-diarylidenyl-n-substituted-piperid-4-one-derived inhibitors of Stat3 pathway activity and uses thereof | STAT3, JAK2, STAT6 | MAPT 4414/4885KDM4E 2481/4885ALDH1A1 928/4885 |
| US-20200399220-A1 | 3,5-DIARYLIDENYL-N-SUBSTITUTED-PIPERID-4-ONE-DERIVED INHIBITORS OF STAT3 PATHWAY ACTIVITY AND USES THEREOF | STAT3, JAK2, STAT6 | MAPT 4414/4885KDM4E 2481/4885ALDH1A1 928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.